INTRODUCTION {#Sec1}
============

Preventable adverse drug events involving intravenous medications (preventable IV-ADEs: injuries owing to intravenous medication errors) occur frequently in intensive care units (ICUs).[@CR1],[@CR2] Many errors occur during medication administration, and calculating infusion rates and programming pumps are high-risk steps.[@CR2],[@CR3] Programmable infusion pumps with safety software ("smart pumps") were designed to intercept such errors by displaying alerts if continuous-infusion dosages exceed hospital-defined ranges or, for one pump, if duplicate infusions are administered.[@CR4]

Three studies indicate that the reprogramming of smart pumps in response to alerts occurs frequently.[@CR5]--[@CR7] However, because most medication errors happen not to cause harm,[@CR2],[@CR8] the ability of smart pumps to reduce IV-ADEs also warrants investigation. One study evaluated whether smart pumps prevent IV-ADEs and found no significant decrease.[@CR8] No studies have assessed how often preventable IV-ADEs actually match smart-pump safety features or whether expanding pump capabilities might prevent additional types of IV-ADEs.

In this study, we sought to determine how frequently preventable IV-ADEs match one smart pump's features and to identify additional smart-pump capabilities. Our ultimate objective was to compare preventable IV-ADE incidence rates between smart pumps and conventional pumps.

METHODS {#Sec2}
=======

Overview {#Sec3}
--------

We used quantitative and qualitative methods to examine preventable IV-ADEs in adult ICUs before and after 2 hospitals replaced conventional pumps with smart pumps.

Setting and Subjects {#Sec4}
--------------------

With assistance from the study sponsor (Cardinal Health, San Diego, CA, USA), we selected 2 hospitals that had implemented their smart pumps in 2003 (Alaris version 5): an academic hospital in the northeast and a nonacademic hospital in the west. We examined 20,000 bed-days of care in surgical, trauma/burn, and medical ICUs, half during conventional-pump study periods and half during smart-pump periods. We obtained Institutional Review Board approvals; informed consent was not required.

Smart-Pump Features {#Sec5}
-------------------

A programmable unit within the pump controlled up to 4 attached infusion devices and recorded ("logged") programming errors, alerts, reprogramming events, and overrides. Before implementation, study hospitals developed software libraries for drugs given by continuous infusion; bolus dosing was not addressed. The manufacturer suggested dosing limits then hospitals made modifications. ICU libraries included over 50 drugs.

Nurses could program the pumps as if they were conventional or use the library's safety features. Once in the library, nurses selected a drug and standard concentration then entered the dose. For weight-based dosing, nurses entered patient weights and doses, then the software calculated flow rates. When doses exceeded library limits or duplicate infusions were programmed, the software provided alerts and prevented infusion until they were addressed; overrides were permitted.

Data Collection {#Sec6}
---------------

This included abstracting medical records and rating suspected ADEs. We did not observe pump use or abstract smart-pump logs.

Critical care nurses (4--5 per hospital; uninvolved in study participants' care) received 4-day trainings in medical-record abstraction and ADE identification (reading manuals, discussing examples, and reviewing sample records). During data collection, nurses recorded clinical and demographic data then used manual trigger-tool review (which uses key words as sentinels to identify ADEs)[@CR9] plus implicit review (professional judgment) to identify suspected ADEs and any events that infusion pumps might have caused. For each suspected ADE, they summarized relevant details of medication therapy,[@CR10] errors, and injuries. Reliability assessment involved reabstracting 100 records.

Four board-certified Internal Medicine physicians (unaffiliated with study hospitals) rated suspected ADEs. Two reviewed each electronic summary individually then met to reach consensus, rating: whether an ADE occurred,[@CR2] drugs involved, routes/modes of administration,[@CR2] preventability,[@CR11] errors involved,[@CR2] and whether errors matched smart-pump functions at each hospital (i.e., whether continuous-infusion doses were outside library limits or present in multiple infusions). Reliability assessment involved randomly selecting 50 suspected ADEs.

Quantitative Analysis {#Sec7}
---------------------

We used SAS version 9.1.3. First, we examined administration routes/modes, drugs, stages in delivery, and errors involved in preventable IV-ADEs overall. Second, we calculated incidence rates (preventable IV-ADEs per 1,000 patient-days in ICU) for preventable IV-ADEs matching smart-pump functions in each study period. Third, we compared total preventable IV-ADEs incidence rates between conventional-pump and smart-pump periods using Poisson regression models that included multiple demographic and clinical variables. We had 80% power (alpha = 0.05) to detect a 46% change. Finally, we determined intracluster correlations for nurse and physician ratings.[@CR12]

Qualitative Analysis {#Sec8}
--------------------

For events matching smart-pump features, we summarized errors involved. For other events, we summarized examples of common errors and explored additional smart-pump capabilities.

RESULTS {#Sec9}
=======

Among 4,604 patients with 20,559 bed-days in ICU, we identified 100 preventable IV-ADEs (4.86 per 1,000 patient-days). Half of preventable IV-ADEs involved continuous infusions and 40% boluses. Morphine, insulin, fentanyl, and propofol represented 44% of all drugs involved. Half of errors occurred during ordering, 14% during administration, and 35% during monitoring. Failure to intervene, failure to monitor (37% combining subtypes, not shown), and overdose were common errors (Table [1](#Tab1){ref-type="table"}). Two preventable IV-ADEs in each study period (4%, 0.19 per 1,000 patient-days) matched smart-pump functions at each hospital (Table [2](#Tab2){ref-type="table"}). No pumps caused any injuries. Table 1Types of IV Medication Errors Causing Preventable IV-ADEs in Both Study Periods CombinedErrors Errors relating to dose of medication received Improper dose: overdose, no. (%)29 (29.0%) Improper dose: underdose, no. (%)3 (3.0%) Improper dose: extra dose, no. (%)0 (0.0%) Wrong strength/concentration: too high, no. (%)1 (1.0%) Wrong rate, no. (%)1 (1.0%) Wrong duration, no. (%)4 (4.0%)Errors relating to administration details Wrong technique, no. (%)5 (5.0%) Wrong drug, no. (%)5 (5.0%) Wrong time, no. (%)1 (1.0%)Errors relating to monitoring for potential problems Failure to monitor: drug--disease interaction, no. (%)5 (5.0%) Failure to monitor: allergy, no. (%)3 (3.0%) Failure to monitor: drug--drug interaction, no. (%)1 (1.0%) Failure to monitor: laboratory, no. (%)9 (9.0%) Failure to monitor: other, no. (%)19 (19.0%)Errors relating to intervening after problems appear Failure to intervene, no. (%)45 (45.0%)Other errors13 (13.0%)Total preventable IV-ADEs\*100\*Each preventable IV-ADE may be associated with more than 1 type of error.IV-ADE = adverse drug events involving intravenous medicationsTable 2Qualitative Analysis of Errors Causing Preventable IV-ADEsIV-ADE DescriptionDescription of Smart-pump FeaturesPreventable IV-ADEs matching existing smart-pump functions at the same hospital and existing smart-pump functionsOverdose: A middle-aged female with a stroke was prescribed an IV labetalol infusion for blood pressure control. Pharmacy sent 2 medication bags to the unit, 1 containing 1 mg/mL labetalol and, 2 h later, another containing 2 mg/mL. The 1-mg/mL solution infused at 100 mg/h and the 2 mg/mL solution infused concurrently in a second line at 140 mg/h. The blood pressure fell to 85/70 then the second infusion was stopped and the blood pressure recovered.Practice standardization: After smart pumps implementation, 1 mg/mL was the only concentration of labetalol used in ICUs at this hospital.Overdose detection: Smart pumps at this hospital alerted nurses when labetalol infused at a dose above 120 mg/h.Duplicate medication detection: Smart pumps at this hospital alerted nurses when labetalol was administered concurrently in 2 different lines.Overdose: A middle-aged male with delerium tremens received a lorazepam infusion at 20 mg/h and subsequently an IV propofol infusion at 70 mcg/kg/min. His blood pressure and oxygen saturation declined, the 2 medications were titrated off over the next hour and a half, and then the blood pressure recovered.Overdose detection: Smart pumps at this hospital alerted nurses when lorazepam infused at a dose above 10 mg/h (or propofol at a dose above 100 mcg/kg/min).Overdose: A middle-aged male with renal failure received increasing doses of an insulin infusion for uncontrolled blood glucose (per protocol), peaking at 24 units/h for blood glucose values in the 400s. Over the next 6 h, the blood glucose declined and the insulin was titrated off, but the blood glucose dropped into the 20s.Overdose detection: Smart pumps at this hospital alerted nurses when insulin infused at a dose above than 20 units/h.Overdose: A young adult male received a propofol infusion for ventilator sedation. It was started at 70 mcg/kg/min and increased to 100 mcg/kg/min 10 min later. His blood pressure fell to 70/50, and then recovered after the propofol was stopped.Overdose detection: Smart pumps at this hospital alerted nurses when propofol infused at a dose above 80 mcg/kg/min.Examples of common preventable IV-ADEs and expanding pump library capabilities to prevent additional IV-ADEsFailure to intervene: A middle-aged female on morphine PCA pump for postoperative pain experienced 3 episodes of vomiting. She received 3 doses of ondansetron and 1 of promethazine. After 24 h, the opiate was changed to hydromorphone and the vomiting stopped.Modifications to intercept errors: For patients on IV opiates, a smart pump could detect when IV antiemetics are given and alert nurses that switching opiates should be considered.Overdose: An elderly female with a stroke and a systolic blood pressure in 190s received 2 doses of IV hydralazine 20 mg 5 min apart. She developed hypotension and a severe brain stem infarct.Modifications to intercept errors: For patients on IV hydralazine, a smart pump could track cumulative doses, have limits per designated period of time, and alert nurses if doses exceeded these limits.Examples of common preventable IV-ADEs and incorporating real-time vital-sign or laboratory test data to prevent additional IV-ADEsOverdose, failure to monitor, failure to intervene: An elderly male was given 100 mcg IV fentanyl bolus and propofol infusion at 35 mcg/kg/min for a bedside procedure. Blood pressure dropped to 60s systolic. He received 250 mL of normal saline, but propofol was not changed. Blood pressure was rechecked 90 min later and was still in 60s systolic.Modifications to intercept errors: For patients on propofol or other vasoactive IV drugs, a smart pump could receive blood pressure data, and alert nurses or shut off when blood pressure remains outside a defined range for more than a few minutes.Modifications to automate tasks: For patients on propofol or other vasoactive IV drugs, a smart pump could receive blood pressure data and titrate the drugs to keep blood pressure within a defined range.Failure to monitor, failure to intervene: An elderly female was started on an IV heparin infusion for acute myocardial infarction. Daily PTT results were repeatedly above therapeutic range. Dose was lowered but PTT was not repeated until the next day when it was still high. Patient developed a retroperitoneal hematoma and died.Modifications to intercept errors: For patients on IV heparin, a smart pump could receive PTT data and alert nurses if PTT were not checked according to the frequency defined in the protocol or if PTT were above or below desired range.Modifications to automate tasks: For patients on IV heparin, a smart pump could receive PTT data and titrate heparin according to a defined protocol. A smart pump could interact with computerized physician order entry, which could order PTT to be checked according to the frequency defined in the protocol.Failure to monitor: An elderly female with end-stage renal failure was a given standard insulin infusion protocol to manage her blood glucose but no glucose was provided via the enteral route or IV. Her blood glucose dropped to 33 then rebounded to over 200 after glucose was given.Modifications to intercept errors: For patients on IV insulin, smart pumps could receive blood glucose data, alert nurses when values fall outside of a protocol, check whether protocols are appropriate for renal function, and alert nurses if no IV glucose is provided.Modifications to automate tasks: For patients on IV insulin, a smart pump could receive blood glucose data and titrate insulin according to a defined protocol.IV-ADE = adverse drug events involving intravenous medications, PTT = partial thromboplastin time

As noted in the [Introduction](#Sec1){ref-type="sec"}, our ultimate objective was to compare total preventable IV-ADEs incidence rates between conventional-pump and smart-pump periods. However, given that few preventable IV-ADEs matched smart-pump features, statistical power was severely inadequate. The conventional-pump rate was 4.78 per 1,000 patient-days and the smart-pump rate was 4.95 (adjusted mean difference 0.04 per 1,000 patient-days, *p* = 0.96).

Event descriptions suggested that expanding smart-pump library applications, integrating pumps with vital-sign and laboratory data, integrating pumps with computerized physician order entry (CPOE), and automating medication titration might prevent additional IV-ADEs (Table [2](#Tab2){ref-type="table"}). The intracluster correlation for nurses identifying suspected events was 0.39. Physician intracluster correlations were: for ADEs, 0.71; preventability, 0.90; and smart-pump preventability, 1.0.

DISCUSSION {#Sec10}
==========

Examining preventable IV-ADEs among 4,600 adult ICU patients, we found that only 4% could be intercepted by a smart pump that detects duplicate and excessive doses of continuous infusions. There were several reasons for the low rate of corresponding events: these pumps did not address boluses, the dosing ranges appeared too wide for certain patients, and monitoring problems were more common than administration ones. Nevertheless, we observed that expanding pump functions and integrating them with real-time clinical data might enable smart-pump technology to reduce other common, harmful errors.

Four evaluations of similar smart pumps came to more positive conclusions. Comparing 426 infused medications with physician orders during a 9-hour period, researchers judged 1 error to be smart-pump-preventable because it was a rate-deviation error involving a pump-programming mistake.[@CR13] Three studies examining smart-pump logs found that reprogramming events, assumed to be intercepted errors, were common.[@CR5]--[@CR7]

Because errors have unpredictable relationships to injuries, however, preventable IV-ADEs must also be examined; for example, 0.9% of medication errors caused ADEs in medical floor units versus 11% in cardiac ICUs.[@CR2],[@CR8] A controlled trial evaluating a similar pump did consider preventable ADEs and found no significant reduction, because of limited power and because nurses used its safety features inconsistently.[@CR8]

In contrast, our analysis revealed that substantially reducing preventable IV-ADEs in ICUs would require smarter pumps. Many preventable IV-ADEs involved failures to monitor for or adequately respond to undesirable medication effects. Smart-pump technology could alert nurses to such failures by integrating infusions with CPOE, and real-time vital-sign and laboratory data. Perhaps more controversially, smart pumps could automate some titration tasks. Intensive insulin infusions seem particularly amenable to automation because complex protocols create many opportunities for error; clinical assessment is rarely required; and an automated technique for tightly controlling blood glucose, the euglycemic glucose clamp, already exists.[@CR14] Others have described closed-loop systems for titrating sedatives.[@CR15]

The manufacturer of the pumps we evaluated has already expanded applications to include boluses, syringe pumps, and patient-controlled analgesia. An integrated bar-code reader has been designed to address wrong-patient and wrong-drug errors. A patient-controlled analgesia pump monitors oxygen saturation and end-tidal carbon dioxide, issuing an alert or shutting off if values deviate from hospital-defined ranges (Butterfield, personal communication, 2006).

As with any technology, new smart-pump capabilities have potential barriers to overcome. Integration with bar coding and CPOE assumes that hospitals are adopting these technologies, which may not be the case.[@CR16] Incorporating real-time vital-sign data may require nursing practice changes. Integration with laboratory data would require software development. Automating monitoring and titration tasks would reduce nurses' opportunities to practice these skills.[@CR17] Finally, new safety technologies can introduce new errors.[@CR18] Consequently, expanding smart-pump applications will require careful development and testing.

Regarding limitations, we may have underestimated events matching smart-pump functions because we could not evaluate smart-pump logs or observe users. Nursing agreement was only fair, possibly owing to insufficient training or reabstracting too few records; other studies have not reported nurse agreement. However, we used standard methods and documented physician agreement comparable to prior studies.[@CR19] We studied 2 hospitals, 1 clinical setting, and 1 time period. Smart-pump technology is evolving rapidly and future research should include non-ICU settings, where IV-ADEs may not be detected quickly.

CONCLUSIONS {#Sec11}
===========

The smart pumps we evaluated are unlikely to reduce preventable IV-ADEs in ICUs because they address only 4% of them. Expanding smart-pump capabilities might prevent more IV-ADEs.
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